Both 100mg and 200mg doses of Pfizer Inc.’s selective JAK1 inhibitor abrocitinib demonstrated statistical significance on a pair of skin-clearance measures as well as a secondary endpoint of reducing pruritus in the Phase III JADE MONO-2 study, the company said on 27 September, confirming data for the drug in atopic dermatitis reported in May.
Pfizer’s Michael Corbo, chief development officer for inflammation and immunology, said the company hopes to file abrocitinib for US Food...